Clinical Trials Browser

Carcinoma, Transitional Cell × trebananib × Genitourinary × Clear all

NCT01907308 2014-04-29

Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma

Phase 2 Withdrawn

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell